Stifel upgraded Inspire Medical Systems from Hold to Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2025 | $175.00 | Perform → Outperform | Oppenheimer |
| 12/2/2025 | $130.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/26/2025 | $165.00 | Hold → Buy | Truist |
| 11/25/2025 | $180.00 | Peer Perform → Outperform | Wolfe Research |
| 11/24/2025 | Hold → Buy | Stifel | |
| 11/4/2025 | $90.00 | Equal Weight → Overweight | Wells Fargo |
| 10/24/2025 | $85.00 | Buy → Hold | Jefferies |
| 9/22/2025 | $89.00 | Buy → Neutral | UBS |
Oppenheimer upgraded Inspire Medical Systems from Perform to Outperform and set a new price target of $175.00
Morgan Stanley downgraded Inspire Medical Systems from Overweight to Equal-Weight and set a new price target of $130.00
Truist upgraded Inspire Medical Systems from Hold to Buy and set a new price target of $165.00
MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) ("Inspire", or the "Company"), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025, and provided its initial full year 2026 revenue guidance. Further, the Company announced the appointment of Matt Osberg as Executive Vice President and Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full Year 2025 Revenue Revenue for the fourth quarter of 2025 is anticipate
MINNEAPOLIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the fourth quarter and full year 2025 after the close of trading on Wednesday, February 11. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q4 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, ple
MINNEAPOLIS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Inspire is scheduled to present at 12:45 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investor
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)
144 - Inspire Medical Systems, Inc. (0001609550) (Subject)
144 - Inspire Medical Systems, Inc. (0001609550) (Subject)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured
MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) ("Inspire", or the "Company"), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025, and provided its initial full year 2026 revenue guidance. Further, the Company announced the appointment of Matt Osberg as Executive Vice President and Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full Year 2025 Revenue Revenue for the fourth quarter of 2025 is anticipate
MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively. "Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, a
Presidio Medical, Inc., a clinical stage company developing a transformational neuromodulation platform, is pleased to announce Richard J. Buchholz will join its Board of Directors. Rick is the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE:INSP), where he has played a pivotal role in driving strategic financial and operational growth for the global leader in the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. "We are excited that Rick is joining the Board of Directors of Presidio Medical at this critical time in our company's journey. His leadership and financial acumen will be instrumental in advanc
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
MINNEAPOLIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the fourth quarter and full year 2025 after the close of trading on Wednesday, February 11. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q4 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, ple
MINNEAPOLIS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2025. Recent Business Highlights Generated revenue of $224.5 million in the third quarter of 2025, a 10% increase over the same quarter last yearAchieved gross margin of 85.8% in the third quarter of 2025Net income was $9.9 million in the third quarter of 2025. Adjusted net income was $11.2 millionIncome per share was $0.34 in the third quarter
MINNEAPOLIS, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the third quarter 2025 after the close of trading on Monday, November 3. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q3 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followi